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roads are more navigable than during
the rainy season. The epidemic strain
then spread in the nonimmune popu-
lation, which had no cohort immune
barrier. All age groups had similar
attack rates, in contrast to epidemics
within the meningitis belt, which
essentially affect children; the death
rate in the absence of appropriate
treatment was 100%. We showed that
in 1999 to 2000 in Yaoundé, a large
city situated in the tropical rainforest
at about 600 km south of the meningi-
tis belt, N. meningitidis was isolated
in 13.4% of cases of bacterial menin-
gitis, and most of the strains isolated
belonged to serogroup A (3).
Serogroup A and W135 meningococ-
cal meningitis increased in Yaoundé
between 1995 and 2000, possibly
attributable to increases in human
exchanges between the northern
provinces (situated within the menin-
gitis belt) and the central and southern
provinces (6).
Other trigger factors frequently
considered responsible for epidemics
within the African meningitis belt are
drought and the “Harmattan” wind
because all major epidemics start at
the driest period of the dry season and
stop with the first rains. The
Harmattan wind rarely reaches South
Cameroon. Precipitation has been
recorded over a number of years at
Fontem Missionary Hospital. From
1995 to 1999, yearly rainfall averaged
2,300–2,500 mm, with only 0–50 mm
from November to March. In the past
5 years, an average of no more than
two consecutive months have been
without rain, whereas almost four
consecutive months without rain
(December to the end of March)
occurred just before the epidemic.
Thus, this outbreak appeared to
result from several factors: 1) a
virulent serogroup A strain belonging
to ST-7 that had been responsible for
recent epidemics in surrounding
countries and was circulating in
Cameroon; 2) the expansion of this
strain, favored by the absence of an
immune barrier in the population and
by commercial exchanges; and 3) an
exceptionally dry season. Outbreaks
of meningococcal disease are not
strictly bound to certain ecologic
conditions occurring within the
meningitis belt but may break out
elsewhere. Since the epidemic
reported here, another meningococcus
Aepidemic (~200 cases) has occurred
at a similar equatorial latitude, near
Bamenda (approximately 100 km
north of Fontem), in 2001 (J.
Kamgno, pers. comm.).
Health authorities should be aware
of the possibility of such epidemics,
be ready to alert medical practitioners
and the public about them as they
occur, and ensure that patients receive
proper treatment and vaccines in these
zones.
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West Nile Virus
Meningitis in
Patient with
Common Variable
Immunodeficiency
To the Editor: Infection by West
Nile virus (WNV) was first recog-
nized in the Western Hemisphere in
1999 in New York (1). Subsequently,
this mosquito-borne flavivirus has
spread westward and has emerged as
an important cause of infectious
meningoencephalitis in the United
States (2). In September 2002, during
a WNV epidemic in Michigan (2), a
38-year-old woman with common
variable immunodeficiency (CVID)
sought treatment at the University of
Michigan Hospital with acute WNV-
associated meningitis. Although per-
sons with CVID are at increased risk
for enteroviral meningoencephalitis, a
greater susceptibility to arthropod-
borne flavivirus infections has not
been reported.
The patient had a history of recur-
rent sino-pulmonary infections and
gastrointestinal giardiasis and salmo-
nellosis; at 33 years of age, she was
diagnosed with CVID that has been
subsequently treated with intravenous
immunoglobulin (IVIG) every 3
weeks. She was in her usual state of
health until 5 days before admission,
when she noted the abrupt onset of
severe headache, followed by temper-
atures up to 39.4°C, progressive pho-
tophobia, nausea, vomiting, and a1354 Emerging Infectious Diseases • Vol. 9, No. 10, October 2003
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transient papular rash on her trunk and
extremities. 
On arrival, the patient reported
marked photophobia. Physical exami-
nation showed a temperature of
40.6°C, heart rate 80 beats per minute,
and blood pressure 122/70 mmHg.
She had cervical tenderness to palpa-
tion and active range of motion with
minimal rigidity. Small, diffuse, non-
tender lymphadenopathy was noted in
the cervical region. No focal or global
deficits were found on neurologic
exam. Results of the remainder of the
physical examination was unremark-
able. Initial laboratory values includ-
ed a peripheral leukocyte count of 3.5
K/mm3 (normal: 4.0–10.0 K/ mm3;
42% neutrophils, 52% lymphocytes,
and 7% monocytes), which was
unchanged from the patient’s baseline
leukopenia. Her serum IgG level was
1,081 mg/dL (620–1,520 mg/dL). 
Cerebrospinal fluid (CSF) sam-
pling indicated the following: erythro-
cytes 3/mm3, leukocytes 77/mm3
(41% neutrophils, 51% lymphocytes,
7% histiocytes), glucose 50 mg/dL
(50–70 mg/dL), and protein 75 mg/dL
(15–45 mg/dL). Results of routine
Gram stain, bacterial and fungal cul-
tures, polymerase chain reaction test-
ing for herpes simplex virus and
Cryptococcus neoformans antigen
were negative. Assay results of the
patient’s CSF for WNV by IgM-cap-
ture enzyme-linked immunosorbent
assay, performed by the Michigan
Department of Community Health,
were positive. 
The patient was initially treated
with parenteral ampicillin, cef-
tazidime, and acyclovir, which were
discontinued within 48 hours. Her
symptoms improved with routine
medical support, and she was dis-
charged on hospital day 5. We were
notified of the positive CSF IgM for
WNV approximately 2 weeks after
the patient was discharged, at which
time her symptoms had completely
resolved. At a follow-up visit 3 weeks
after her hospitalization, the patient
had no residual symptoms of menin-
gitis.
Patients with agammaglobuline-
mia, either common variable or X-
linked, are known to be susceptible to
recurrent infections (3). Bacterial
infections are the best described;
however, chronic enteroviral menin-
goencephalitis is also associated with
deficiencies in B-cell immunity (4–6).
Although the role of immunoglobu-
lins in host defense against WNV
infection is not completely under-
stood, evidence suggests that humoral
immunity protects against WNV
infection and severe disease (7–9).
WNV is a single-stranded RNA
virus of the family Flaviviridae. Its
genome is processed to eight proteins,
including the envelope (E) glycopro-
tein, the matrix protein, the nucleocap-
sid protein, and five nonstructural pro-
teins (7). E-glycoprotein antibodies
develop during human WNV infection
(8), and passive immunization of mice
with E-glycoprotein antiserum pro-
tects against WNV infection and death
(7,8). In addition, IVIG therapy was
associated with recovery from WNV
meningoencephalitis of an immuno-
suppressed 70-year-old woman (9).
Although our patient had normal lev-
els of serum IgG at the time of illness,
viral meningitis may occur in agam-
maglobulinemic patients despite regu-
lar IVIG therapy (10).
This case demonstrates the need to
consider WNV in patients with CVID.
Our patient recovered promptly, with-
out evidence of neurologic sequelae,
despite her underlying immunodefi-
ciency. More experience is needed to
provide a better understanding of the
relationship between CVID and
WNV.
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